Clinical Trial Update: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide) [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of Efocipegtrutide (HM15211) in obesity; results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Efocipegtrutide (HM15211) (Efocipegtrutide)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Obesity | Phase 1 | Status: COMPLETED | Results posted: 2024-05-17